

**Drug plans—Cont.**

- Andre statements, 10:21; 14:27  
 Blue Cross, 13:6  
*See also* Drug plans—Premiums  
 Drugs, delisting, welfare recipients access, 12:58, 60-1, 64, 68  
 Flow-through effect, cost/price increases, Bill C-22, 6:73-4, 87-8;  
 8:22; 10:21-2  
 Additional benefits, eroding, 10:23-4; 14:27  
 Generic, negotiating, multinational pressure, Ford Motor Company  
 of Canada example, 6:80; 14:21, 27-8  
*See also* Drug plans—New York State—Provincial  
 Hospital plans, origin, 12:68  
 Manitoba, 11:22; 12:57, 63, 68  
 Pharmicare program, Bill C-22 bankrupting, 11:31  
 New York State, generic drugs, greater use, 12:26  
 Ontario, 11:22, 59, 65-6; 15:57-8  
 Eligibility, King recollections, 15:58  
 Payment methods, 9:34, 46; 11:54  
 Premiums, rising rates, Ontario Blue Cross 47% increase, etc.,  
 11:54; 15:62, 72, 81  
 Private, premiums, Bill C-22 effect, 6:62  
 Coverage, Bill C-22 transitional provisions extending, proposal,  
 10:22  
 Provincial  
 Accessibility, 6:51, 62; 15:61-2, 75-6  
 Generic drug companies stimulating, 15:82  
*See also* Cystic fibrosis  
 Quebec, 12:22, 24-5, 55, 58, 64  
 Saskatchewan, 11:22, 26, 29-31; 11:65-6  
 Senior citizens, 15:58, 61  
 United States, comparing, 12:26; 14:28; 15:61  
*See also* Canadian Automobile Workers Union; Drugs and  
 pharmaceuticals—Provinces

**Drug prescriptions**

- Compendium of Pharmaceuticals and Specialities*, abolishing,  
 proposal, 15:75  
 Growth, annual, medicare contributing, 15:72-3  
 Prices, Bill C-22 effect, 15:80  
*See also* Community Health Co-operative Federation of  
 Saskatchewan; Consumers

**Drug Prices Review Board, 10:10, 16, 45**

- Alternatives, etc., 6:14-5, 59-60, 63; 8:9, 21; 15:33  
 Appointments process, members, budget, etc., 3:73-4; 5:15-6; 6:30,  
 68; 8:62; 11:20, 24-8; 13:24; 14:52; 15:50, 52; 16:22, 24; 17:33-4  
 Governor in Council appointments, 17:34-5  
 Complaints, review process, appeal, 5:26-9; 6:8, 13-6, 22-3; 6:64-5;  
 11:25; 12:56; 13:13; 16:24-5, 75  
 Consumers' groups/health professionals, representation, proposal,  
 6:63, 68-9, 71-2; 13:21  
 Clinical pharmacologist, need, 15:46  
 Constitutionality, legal implications, 13:13, 24; 16:66, 68-9, 73, 76  
 Supreme Court of Canada decision 1976, Laskin judgement,  
 16:67  
 Industry representatives, conflict of interest, 6:63  
 Legislation, Bill C-22 establishing, effect, 1:12, 15, 18, 31, 33; 3:11,  
 15-6, 21, 29-30, 48, 67, 71-3; 5:19-21, 24-6, 28, 30-3; 6:24, 62,  
 84-5; 7:15; 9:27, 36; 11:19, 63, 77; 12:62; 13:15-6; 14:12; 15:27,  
 58-9, 75, 77-8, 81  
 Prices, introductory, difficulty determining, 5:13-5, 22-3, 29; 6:8,  
 24-5, 53-5, 63, 70-1, 77-8, 84, 86; 7:5, 9-10, 12-3, 15; 8:7, 26, 63;  
 10:22, 24, 30-1; 11:27-8; 12:65; 13:9-10; 14:15-6, 26, 41, 52, 63;  
 15:25, 38, 49, 51, 89; 16:23, 70-1; 17:36-8  
 Progressive Conservative Party position, confusing/hypocritical,  
 6:24, 60; 11:71; 12:56-7, 67; 14:29; 15:22, 36  
 Provinces, interaction, 3:28-9, 35-6

**Drug Prices Review Board—Cont.**

- Regulatory powers, sanctions, etc., 1:14, 38-9; 5:12-3; 6:16-7, 23-5,  
 30, 64, 72; 11:20, 24-5, 52, 70, 75; 12:44, 47, 49, 51, 70-1, 73-4;  
 13:7, 12-4, 16, 18-20, 30-1; 14:9, 29, 49, 63, 69-72; 15:8, 10-1,  
 20, 23, 30, 32, 35-6, 41-2, 48-50, 89-90, 93; 16:22-3, 71-5;  
 17:26-9, 31-2  
 Broadening, proposal, 6:32  
 "Draconian", 6:8, 22  
 Price evasion tendency, resulting, British/French examples,  
 information, tabling, 6:25, 38, 50, 53  
 Regulatory capture, multinational influence, Eastman credibility,  
 etc., 6:30, 50-1, 53, 55, 65, 72; 11:25; 14:68-9, 71  
 United Kingdom, comparison, 6:54  
 Reporting responsibilities, company research and development, 6:8;  
 17:38-41  
 Scientific Research Tax Credit Program, money-waster,  
 comparison, 8:63; 12:55  
 Subcommittee, expert, establishing, 13:21-3, 29-30; 15:46-7, 49-51  
*See also* Brand name drugs; Drugs and  
 pharmaceuticals—Costs/prices, Ceiling prices—Orphan drugs;  
 Drugs and pharmaceuticals industry—Promotion expenditures  
 to sales; Review boards

**Drugs and pharmaceuticals**

- Benefits, 10:10  
 Cost components, 12:31  
 Costs/prices, Bill C-22 increasing, \$650-660 million aggregate  
 estimate, 1:13, 15-8, 28-33, 37, 39-40; 3:10-11, 14, 16, 19, 30-1,  
 49-50, 60, 67-71; 5:11, 17-9; 6:19-20, 39-40, 46-7, 61-2, 72-3, 75,  
 87-8; 8:5-7, 55-6, 66-8; 10:9, 19, 21; 11:18-9, 47-9, 59-60;  
 12:21-2, 26-7, 57-9, 61-2, 73; 13:8-9, 17, 26-7, 36-7; 14:9, 19, 22,  
 29, 38, 55-6, 58-9, 66, 70; 15:21, 24-5, 28-9, 32, 56, 60, 63, 85,  
 88-9  
 Access, impeding, impact on low income Canadians, 6:74-5, 77;  
 7:7; 11:40, 51-5, 60-4; 15:35  
*See also* Drug plans—Access  
 Andre statements/estimates, misleading, 10:28-9; 15:87-90  
 Angus Reid & Associates poll, 11:56-7; 15:92  
 Canadian Drug Manufacturers Association/Coopers and Lybrand  
 study, 1:25; 3:19-21, 50; 6:54; 8:62; 14:19; 16:86  
 Ceiling prices, Drug Prices Review Board establishing, Consumer  
 Price Index determining, proposal, 3:74; 5:20; 11:20-1, 25  
 Comparison shopping, *Protegez-vous* magazine survey, price  
 variations, 1:35-7; 6:86-7; 9:52; 10:29, 31; 11:30, 50; 15:39  
 Compulsory licensing/Canada Health Act, effect, 9:50; 14:55, 70  
 Consumer and Corporate Affairs Department, white paper, 1983,  
 6:81; 15:86  
 Consumer Price Index comparison, 5:20; 6:77-8, 83; 7:5; 11:65  
*See also* Drugs and pharmaceuticals—Costs/prices, Ceiling  
 prices  
 Consumers Association of Canada estimates, 6:20-2, 27-8, 29-30;  
 8:62-3; 12:21  
 Consumers' organizations' concerns, 1:25-6  
 Deterrent fees, increasing, Manitoba example, 5:18; 6:67; 12:25  
 Fraser Institute findings, 12:73  
 Green Shield Prepaid Services Inc. estimates, 6:76, 88; 8:62;  
 10:23, 25; 11:48; 14:27  
 Insurance rates, United States, affecting, 3:27-8, 54, 64  
 International comparison, 3:7  
 Introductory price levels, 5:20; 6:80-1  
 Kempling, personal recollections, 6:43-4, 8:27; 10:31  
 Legislation, current, comparison, \$211 million dollar savings,  
 Eastman report estimates, 1:43-5; 3:30; 5:17-8; 6:15-6, 27-8,  
 78, 79-80, 83; 8:11, 61; 9:25; 12:24, 57, 69; 13:26-7; 14:13-4,  
 55, 62-3, 69-70, 73-5; 15:37, 62, 80, 88; 16:16  
 Manitoba government estimates, 15:91